ã¡ãã£ã¢èšäº
ãã³ããã«ã¯ã³ãããã¶ã€ãããã®çºæ³ã§æ°åã³ãããŠã€ã«ã¹ãæéã§ããå¯èœæ§
ããºãææ°ããŒã¯ 484
twitterã³ã¡ã³ã 183ä»¶äž 101ïœ183件
æ¯æ§ã®åŒ±ãã³ãããŠã€ã«ã¹äœã£ãŠã°ããŸãã°âŠã£ãŠæéäž5åãããåããæ°ãããã
çŽ äººèãã ãã©ãææåãÎŽãã匷ããã°åãŠããããã
çŽ äººèãã ãã©ãææåãÎŽãã匷ããã°åãŠããããã
åææ¬ é¥ãŠã€ã«ã¹ãã
> ãæ¬ é¥å¹²æž(DI)ç²åããšåŒã°ããŠããŸã
> SARS-CoV-2ã®ã²ãã ã90ïŒ ã«ããããŠ
ã©ã®èŸºãã©ã®äœã«ããããŠããã®ã ããïŒãšæã£ããåèãžã®ãªã³ã¯ããã£ãïŒOpenAccessïŒ
ãã®å³1ãèŠããšççž®çã®ä»ãæ¬ é¥çããããœãã
> ãæ¬ é¥å¹²æž(DI)ç²åããšåŒã°ããŠããŸã
> SARS-CoV-2ã®ã²ãã ã90ïŒ ã«ããããŠ
ã©ã®èŸºãã©ã®äœã«ããããŠããã®ã ããïŒãšæã£ããåèãžã®ãªã³ã¯ããã£ãïŒOpenAccessïŒ
ãã®å³1ãèŠããšççž®çã®ä»ãæ¬ é¥çããããœãã
èå³æ·±ããã©ãã»ãŒç¢ºå®ã«æ°ããªé°è¬è«ã®ãã¿å
ã«ãªãã ãããªâŠã
ãªãããããã¹ãç®±éããããšããŠãããâŠ
ãªãããŸãå±ãªã£ããããã®ãâŠâŠ
次ãã次ãžãšâŠ
次ãã次ãžãšâŠ
ãè²åvs䌜å»åãã£ãŠèšãããŠãŠã¯ãã¿
ããããã®ç 究ãæåãããããŒãã«è³ããã€ãã¯ããŒã ã«1åã®ãšããã1人ã«1åããã¡ããïŒ
ãã ããâŠ
ãããªãã¯ã¹ã®ããªãšã¹ãã¹ã¿ãããªæããïŒ
ãŸã ãŸã ã©ããªããã¯ããããªããã©ãããããç 究ãé²ãã°æããæªæ¥ãæåŸ
ããŠãè¯ãã®ã§ããããïŒð¥º
å°é家ã®çæ§ã«æè¬ãããããŸããã
å°é家ã®çæ§ã«æè¬ãããããŸããã
ãªãã»ã©ãæªã«ã¯æªãã
ç¡å®³ãªãŠã€ã«ã¹ãå¢æ®ãããŠã
æ害ãªãŠã€ã«ã¹ã®å¢æ®ãé²ããšð€
æ害ãªãŠã€ã«ã¹ã®å¢æ®ãé²ããšð€
ðŠ
ãŠã€ã«ã¹ã®è€è£œãç¹°ãè¿ããããšããŸãã«éºäŒç©è³ªã®åæã«å€±æããŠã€ã«ã¹ã®ã²ãã ã®äžéšãæ¬ æããããšããããŸããã²ãã ãæ¬ æãããšããŠã€ã«ã¹ãšããŠæ¯ãèãã®ã«å¿ èŠãªã¿ã³ãã¯è³ªãåæã§ããªãã®ã§ããã®ãŠã€ã«ã¹ã¯æ£åžžã«å¢æ®ããããšãã§ããŸããã
ãŠã€ã«ã¹ã®è€è£œãç¹°ãè¿ããããšããŸãã«éºäŒç©è³ªã®åæã«å€±æããŠã€ã«ã¹ã®ã²ãã ã®äžéšãæ¬ æããããšããããŸããã²ãã ãæ¬ æãããšããŠã€ã«ã¹ãšããŠæ¯ãèãã®ã«å¿ èŠãªã¿ã³ãã¯è³ªãåæã§ããªãã®ã§ããã®ãŠã€ã«ã¹ã¯æ£åžžã«å¢æ®ããããšãã§ããŸããã
ãã®æã®RNAãŠã€ã«ã¹ã®ã²ãã RNAå¢å¹
éçšã§èŠãããDIç²åïŒdefective interferenceïŒããã³ããæ²»çã«äœ¿ãããšããè©Šã¿ã
çºæ³ã¯é¢çœãããäžæãè¡ãããªïŒ
çºæ³ã¯é¢çœãããäžæãè¡ãããªïŒ
ãã®éã®ããã«ã¿æ ªãã©ã ãæ ªãé§éãããã®ãšåãçå±ã§ããããïŒ
ãžããã
äžçã«ã¯å€©æã沢山ããŠããâ
ãŸãã«ããã±ã¢ãã«ã¯ãã±ã¢ãã¶ã€ããã ããã®åžžç€çµèµã¹ã¿ã€ã«
ãªãæ ç»ã§ã®çµæã¯âŠâŠ
ãªãæ ç»ã§ã®çµæã¯âŠâŠ
ããæ¬åœã«ãäž¡é䞊ã³ç«ãããåæ¹å
±åããã«ãªãïŒ
ãåã£ãã»ãã人é¡æ倧ã®æµãã«ãªããªãïŒ
ãåã£ãã»ãã人é¡æ倧ã®æµãã«ãªããªãïŒ
ç§ãè²åã«ã¶ã€ããã£ãŠããšã§ããïŒ
æ匷ã®åªããã§ããŸããïŒ
æ匷ã®åªããã§ããŸããïŒ
ãã¬ããã¹ãã ãšæãããæ»èªåŸ
ã¡ã ãã©ãããããADEèµ·ããæãããã
ããããåå Žç
ããè»éã«ä¹ã£ãããããããŠã£ã«ã¹æ§ã®ç
æ°ã«å¹ãããããïŒ
ãšããããä»ã§æåããŠãäŸããªããããªã®ã¯é£ããã®ãäºç®ãä»ããªãã£ããããªã®ã
ãšããããä»ã§æåããŠãäŸããªããããªã®ã¯é£ããã®ãäºç®ãä»ããªãã£ããããªã®ã
ã©çŽ 人ã®çåãªãã ãã©
çžæ®ºãããªãéã«ã¿ãã°ã«çµãŸãããã€ãããªïŒ
çžæ®ºãããªãéã«ã¿ãã°ã«çµãŸãããã€ãããªïŒ
è²åVS䌜怰åã§è²åãšäŒœæ€°åãæŠãããŠå士èšã¡ãããããšãããã©æåŸã¯åäœããŠæ匷ã®åªããèªçãããã
ãŸããšãã§ãããã®ãåºãŠãããª
æ¬ é¥ã®ãããŠã€ã«ã¹ãçšããŠCOVID-19ã®æ²»çãã§ããå¯èœæ§ã瀺ããã®ã¯ããã³ã·ã«ããã¢å·ç«å€§åŠã®çç©åŠåææã§ãããã«ã³ã»ã¢ã«ã±ããã£æ°ãã®ç 究ããŒã ã
ãæ¯ããã£ãŠæ¯ãå¶ããã£ãŠãã€ããªð€
ç 究è ã®äººãã¡ãæ¥ã 倧å€ã§ã¯ãããªâŠâŠ
ç 究è ã®äººãã¡ãæ¥ã 倧å€ã§ã¯ãããªâŠâŠ
ææªãªæªéåäœããŠãæ°åã³ãããŠã€ã«ã¹ã®æ¯æ§ãæã¡éåžžãã3åéãå¢æ®ããããŠã€ã«ã¹ãçºçãããããããããªããã£ãŠäžå®ãã
ã³ãããšãã£ããã§ç¡å®³ã§å¢æ®ã®éã人工ãŠã€ã«ã¹ãã¶ã€ããŠã掻åãä¹ã£åã£ãŠããŸãããšããããšãããã
æèœãªæµããç¡èœãªå³æ¹ãåä»ã£ãŠã®ã¯ããŠã€ã«ã¹ã«ãå¹ãã®ã ããã
>ä»åæ°ãã«çºè¡šãããè«æã§ãæ¬ é¥ã®ãããŠã€ã«ã¹ãçšããŠCOVID-19ã®æ²»çãã§ããå¯èœæ§ã瀺ããã®ã¯ããã³ã·ã«ããã¢å·ç«å€§åŠã®çç©åŠåææã§ãããã«ã³ã»ã¢ã«ã±ããã£æ°ãã®ç 究ããŒã
ã€ããŒå¥Žã«ã¯ã€ããŒå¥Žã¶ã€ããã ãçè«
ãããçŽ äººèãã§æã£ãããšç 究ããŠã人ããããããª
è²åvs䌜怰åçè«ããã
U3ãcloudsmartch2ãå¥çŽæå
¥åã§
åæè²»çš500åOFF
U2sãã¡ã(smart1000)ã³ãŒãå ¥åã§
åæè²»çš1000åOFF
åæè²»çš500åOFF
U2sãã¡ã(smart1000)ã³ãŒãå ¥åã§
åæè²»çš1000åOFF
æ°åã³ããã«æ¹å€ããã³ãããŠã€ã«ã¹ãã¶ã€ãã話ã¯ãã¿ã
ã©ãèããŠãã³ã³ãããŒã«äžè¯ã«ãªãã®ç®ã«èŠããŠãããâŠ(Îââ౪ââïœ)
ã©ãèããŠãã³ã³ãããŒã«äžè¯ã«ãªãã®ç®ã«èŠããŠãããâŠ(Îââ౪ââïœ)
ãšã€ãªã¢ã³VSãã¬ãã¿ãŒãšããã¬ãã£VSãžã§ã€ãœã³ãšãè²åVS䌜怰åã¿ãããªã¢ã³ãïŒ
ãªãã»ã©ð³âŒïž
çŽ äººèããšããŠã¯æ¬ é¥ãŠã£ã«ã¹ãå€ç°ããŠã€ãããªã£ããããªãããšæã£ãŠããŸãã
ã¯ã¯ãã³ãæã€ãšé ãçã
ã³ããã«äººå·¥ã³ãããã¶ã€ããŠæéãšãFOXDIEããªïŒw
Pocket New item archived:
ããã«å¯Ÿãããã³ã°ãŒã¹ã¿ãããªããšã«ãªããªãããšãç¥ãã
ãããå€ç°ããŠåŒ·æ¯åããŠäººé¡æ»
亡ãšããã¹ããŒãªãŒããæãã€ããªãã
ããããçºæ³ã§æ¥ãã(ΊÏΊ)
å®å
šã«äœ¿ãã«ã¯10幎ããããããããã ãã©èå³æ·±ãçŸè±¡
ãŸã10幎ãçµã£ãããããã«ã³ããæã蟌ãã§ãããïŒãã©ã°
ãŸã10幎ãçµã£ãããããã«ã³ããæã蟌ãã§ãããïŒãã©ã°
人工çã«åæããç¡å®³ãªSARS-CoV-2ã®æ¬ é¥åã䜿ãäºã§ãCOVID-19ã«å¯Ÿæã§ããå¯èœæ§ããããšã®è«æãçºè¡šð§
æ ç»ã§ã¯ãããªããšãããšæäœã®å€±æã§ããã«åŒ·åãªãŠã€ã«ã¹ãçèªããïŒ
èå³æ·±ãããå€ãªäººå·¥ãŠã€ã«ã¹ãçã¿åºãã¬ãããæ
éã«é¡ãããã
èªãã ãããããèãããªã
ãããåããèšã£ãŠãããÎŽæ ªãæ·æ±°ããææåãæã€ãæ害æ§ã¯äœãå€ç°æ ªã§ÎŽæ ªã朰ããäœæŠãåé¡ã¯ããã€ããååºŠÎŽæ ªçšåºŠã®æ害æ§ãæã€æŽã«ææå匷ãã€ãã«å€ç°ããå¯èœæ§ãã§ã¯ãããâŠã
人工åæãŠã€ã«ã¹ãç©ãããæ¯æ§ãç²åŸããæªæ¥ããèŠãã.
ãæ¯ã以ãŠæ¯ãå¶ãããšããæ¥æ¬èªããã£ãŠãªâŠâŠ
ããã¯ã¡ãã£ãšãããããªã¹ããŒãªãŒã
ã¯ãŒã«ãã»ãŠã©ãŒZã¿ãããªè©±ããð³
ïŸïŸïŸïœ¶ïŸïœ³ïœ¹ïŸïŸ
ïŸïŸïŸïœ¶ïŸïœ³ïœ¹ïŸïŸ
èªåã§ãŠã€ã«ã¹ã¯æ¹é ã§ãããšèšã£ã¡ãã£ãŠãŸããïŒð€ð
æ©éããããåå Žçã¿ãããªè©±ãw
è²åvs䌜怰åã¿ãããªã¿ã€ãã«ãããŠ
è²ã
ããæ¹ã£ãŠãããã ãªã
ãåãç©ã«ã¯åãç©ã¶ã€ããã ãïŒããïŒ(^^;
éºäŒåã ããæäžããmRNAã¯ã¯ãã³ãšã©ãéã£ãŠç¡å®³ãŠã€ã«ã¹ãã®ãã®ã䜿ããšããçºæ³âŠã®ç解床ã§ãã£ãŠãã®ããª
ã¯ã¯ãã³ãå¹ããªããããªå€ç°æ ªãåºãŠæ¥ãå Žåãããææåã匷ã匱æ¯åãããŠã€ã«ã¹ãäœæããŠè延ããããšããæ段ã¯èããããŸããã
>ã²ãã ãçããããã§SARS-CoV-2ããçŽ æ©ãèªå·±è€è£œããSARS-CoV-2ã®å¢æ®ãé»æ¢
ãåœé»ãã³ãããšã殺è«ãã³ãããæãåºãã
ãåœé»ãã³ãããšã殺è«ãã³ãããæãåºãã
å°ã£ãæã¯çŽ«å€ç·ãåœãŠããšãã£ãšããéã«åŽ©å£ãããã¿ãããªå®å
šè£
眮ã欲ããã
å€æ¥çç©ã®é§é€ãšãã«äœ¿ãããææ³ã ãšæã£ãŠããã©ããŠã€ã«ã¹ã«ãå¹æããã®ãâŠã¢ãããžãŒå€§å
šãªããã®ããããäžã«ç«ã¡äžããã
æ£åžžãªã³ãããŠã€ã«ã¹ãšããããããããããã
ãææåã ããã¡ããã¡ãé«ããŠã»ãŒç¡å®³ãªå€ç°ãçŸãããå¯èœæ§ãŸã§ã¯èããããšããã£ããã©ãããã人工çã«äœãå¯èœæ§ãŸã§ã¯èããããšããªãã£ãããªãã»ã©ã
äžã®äžã倩æã£ãŠãããã ãã
å±±ç«äºã§ç«ã䜿ã£ãŠæ¶ç«ããã®ãšäžç·ã®æ¹æ³ã
å±±ç«äºã§ç«ã䜿ã£ãŠæ¶ç«ããã®ãšäžç·ã®æ¹æ³ã
å€å
žçSFã ãšå¶åŸ¡ã§ããªããªã£ãŠãã€ãªãã¶ãŒããããã€ã
â
â
ðð
"
"
æ¬ é¥ã³ãããŠã€ã«ã¹
VS
æ£åžžã³ãããŠã€ã«ã¹
ãšãããŒã¯ããŒããŒæããã£ãŠå¥œãð€
VS
æ£åžžã³ãããŠã€ã«ã¹
ãšãããŒã¯ããŒããŒæããã£ãŠå¥œãð€
æ¯ããã£ãŠæ¯ãå¶ãã®ããžãªãã€ãããããªããäžåŠè«æŸé£Œæ³ã¿ããããªã('Ï')
è²åvs䌜怰åãèŠãããªã£ã
æ¬ é¥ã®ããCOVID19ã®ãŠã€ã«ã¹ã人工çã«äœã£ãŠæ£åžžãªCOVID19ã«ææããŠããåäœã«æ³šå
¥ããããæ£åžžãªãŠã€ã«ã¹ã®å¢æ®ããã»ã¹ãä¹ã£åã£ãŠãŠã€ã«ã¹å¢æ®ãé»å®³ãããšã®ããšã
ãã±ã¢ã³ã«ã¯ãã±ã¢ã³ãã¶ã€ããã ãã£ïŒ
ç§ã®çŽæãã絶察ã«ãã£ã¡ããã¡ã ããšåããŠããŸããçç±ã¯èª¬æåºæ¥ãŸããããäœãã絶察çã«ã€ããã§ãã
ãåãç©ã«ã¯åãç©ã¶ã€ããã ãïŒïŒãæŠæ³ãã³ããã«ãæå¹ãšã¯ãªã
ãããã話é¡ãèŠããšããã®ãã²ãã ãæ¬ æããæ°åã³ãããŠã€ã«ã¹ããå€ç°ããŠå€ãªæ©èœãæèŒãããããªãã®ããå¿é
ã«ãªãã
äžæ¬éãã©ã¹éRNAãæã€ãŠã€ã«ã¹ãçãèŠãªãäºã ã
ð
ð
ãåºæ / å³éžã
ð
ãåºæ / å³éžã
ã¯ã³ããŒã¹ã®æ°·é¬Œçãªçºæ³ãããªãã£ããã
å㞠次ãž
ããã¡ãã£ãšå®éšå°ã«ãªã£ãŠã¿ããæ°ã¯ãããã